Literature DB >> 22749215

On the horizon: flexible immune recognition outside lymphocytes.

Wolfgang E Kaminski1, Alexander W Beham, Julia Kzhyshkowska, Alexei Gratchev, Kerstin Puellmann.   

Abstract

Since decades there is consensus among immunologists that in jawless and jawed vertebrates flexible immune recognition is strictly confined to the lymphoid lineage. In jawed vertebrates the adaptive immune system is represented by two lineages of lymphocytes, B cells and T cells that express recombinatorial antigen receptors of enormous diversity known as immunoglobulins and the T cell receptor (TCR). The recent identification of recombined immune receptors that are structurally based on the TCR in subpopulations of neutrophils and eosinophils (referred to here as TCR-like immunoreceptors, "TCRL") provides unexpected evidence for the existence of flexible host defense mechanisms beyond the realm of lymphocytes. Consistent with this, subpopulations of monocytes and macrophages from humans and mice now have also been shown to constitutively express recombined TCR-like immunoreceptors. Available in vitro evidence suggests that the TCRL in macrophages may exert functions as facilitators of phagocytosis and self-recruitment. More importantly, our recent findings that the macrophage-TCRL is implicated in granuloma formation in tuberculosis and the neutrophil-TCRL is associated with autoimmune hemolytic anemia establish for the first time a link between myeloid recombinatorial immune receptors and clinical disease. The discovery of recombined TCR-like immune receptors in granulocytes and macrophages extends the principle of combinatorial immune recognition to phagocytic cells. Conceptually, this unifies the two hitherto disparate cardinal features of innate and adaptive immunity, phagocytic capacity and recombinatorial immune recognition on a common cellular platform. Moreover, it strongly suggests that flexible host defense in vertebrates may operate on a broader cellular basis than currently thought.
Copyright © 2012. Published by Elsevier GmbH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749215     DOI: 10.1016/j.imbio.2012.05.024

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  7 in total

1.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

2.  Extralymphocytic flexible immune recognition: a new angle on inflammation and aging.

Authors:  Wolfgang E Kaminski; Alexander W Beham; Kerstin Puellmann
Journal:  Aging Dis       Date:  2012-09-19       Impact factor: 6.745

Review 3.  Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages.

Authors:  Leslie Chávez-Galán; Maria L Olleros; Dominique Vesin; Irene Garcia
Journal:  Front Immunol       Date:  2015-05-26       Impact factor: 7.561

4.  Circulating monocytes and tumor-associated macrophages express recombined immunoglobulins in glioblastoma patients.

Authors:  Svenja Busch; Marina Talamini; Steffen Brenner; Amr Abdulazim; Daniel Hänggi; Michael Neumaier; Marcel Seiz-Rosenhagen; Tina Fuchs
Journal:  Clin Transl Med       Date:  2019-06-03

Review 5.  Tumor-Associated Macrophages: Recent Insights and Therapies.

Authors:  Jiawei Zhou; Ziwei Tang; Siyang Gao; Chunyu Li; Yiting Feng; Xikun Zhou
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

6.  Expression of combinatorial immunoglobulins in macrophages in the tumor microenvironment.

Authors:  Tina Fuchs; Martin Hahn; Lukas Ries; Sophie Giesler; Svenja Busch; Chunlin Wang; Jian Han; Torsten J Schulze; Kerstin Puellmann; Alexander W Beham; Wolfgang E Kaminski; Michael Neumaier
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

7.  Trilineage Sequencing Reveals Complex TCRβ Transcriptomes in Neutrophils and Monocytes Alongside T Cells.

Authors:  Tina Fuchs; Kerstin Puellmann; Chunlin Wang; Jian Han; Alexander W Beham; Michael Neumaier; Wolfgang E Kaminski
Journal:  Genomics Proteomics Bioinformatics       Date:  2021-03-02       Impact factor: 6.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.